Gut Microbiota and Diabetic Kidney Diseases

Cardiometabolic diseases appear to be closely linked to the metabolic pathways triggered by the interaction of nutrients with the intestinal flora, and the emerging research in the last decade supports clear roles for microbiota in early development and progression of cardiometabolic risk. Identification of factors that influence gut microbiome composition and function and circulating biomarkers with prognostic value may help to identify relevant pathophysiological processes, to explore how changes in microbiota and microbial metabolism influence host metabolism and cardiometabolic risk and to improve preventive risk reduction. Recently, development of omics technologies has improved biomarker discovery, leading to the identification of a number of disease-associated microbial species and their metabolic products and several potential targets for diagnostic or therapeutic use. This reference work is strong informative about the role of the gut microbiome in organism metabolism and fully discusses the relationship between gut alterations and/or gut microbiome-derived metabolites and the pathogenesis of many diseases, as well as recent advances in clinical applications of microbiome and microbial effector molecules. It clearly shows how the microbiome research is a growing field in molecular and clinical sciences, due to technical advances based on highthroughput genetic sequencing technologies and omics analyses that empower systems biology-based methods for precision health monitoring and treatment. It will help in understanding that high diversity of the microbial communities in the gut is important to preserve health and microbiome alterations, not only in nutritionassociated diseases like obesity and diabetes, but also in many chronic inflammatory, cardiovascular, oncological, and neurological disorders. Written by renown experts in the field, this reference work is intended for clinicians, residents, specialists, and physicians involved in the diagnosis and treatment of affected patients.